Clinical trial BiRD
A Retrospective and Prospective Observational Study of ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice Belgian ibrutinib Real-world Data (BiRD)
| Cancers | |
|---|---|
| Organ | LLC |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Prospective observational study
|
| Academic trial | Non |
| Sponsor | Janssen-Cilag N.V. |
| BECT Identifier | B322201628075 |
| Inclusion criteria | patients that have initiated reimbursed ibrutinib therapy on or after its launch (via the eHealth procedure) or participated in the Medical Need Program for CLL or MCL and switched to reimbursed ibrutinib on or after 1 August 2015 or had started treatment |
| Last update |